DNA cross-link repair 1AGenealiases: PSO2 · SNM1 · SNM1A
Q-omics provides the consensus-scored DCLRE1A profile across patient tissues and cancer cell-line models. DCLRE1A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCLRE1A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DCLRE1A RNA expression shows 20,142 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where DCLRE1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCLRE1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCLRE1A survival associations across molecular data types. DCLRE1A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCLRE1A RNA expression–survival associations across cancer types. High DCLRE1A expression shows unfavorable associations in KICH, UVM and LIHC, but favorable associations in KIRC, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DCLRE1A RNA expression.
This table summarizes DCLRE1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DCLRE1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCLRE1A shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LUAD, COAD and STAD. The HNSC box plot shows higher DCLRE1A RNA expression in tumor versus normal tissue (log2 FC = +0.737, t-test p < 0.001).
This table shows molecular features associated with DCLRE1A in patient tissues and cancer cell lines. In patient samples, DCLRE1A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCLRE1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
